We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Helps Identify CV Patients Most at Risk

By LabMedica International staff writers
Posted on 19 Feb 2018
A new blood test could provide a clue as to why some patients are at higher risk of cardiovascular disease risk after suffering a heart attack, which may help scientists to identify new targets for reducing the risk and eventually lead to more effective treatments.

Adverse events, including cardiovascular (CV) death, remain common following acute coronary syndrome (ACS). More...
Intensive antithrombotic therapies, including potent P2Y12 inhibitors and the addition of low-dose anticoagulant therapy, have all resulted in improved outcomes but increased the risk of major bleeding events.

An international team of scientists collaborating with their colleagues at the University of Sheffield (Sheffield, UK) obtained blood samples from a sub-set of 4,354 patients with acute coronary syndrome as they were discharged from hospital. High-throughput turbidimetric analysis was performed in flat-bottomed, polystyrene 96-well plates using a dedicated Multiskan FC plate reader.

Studied variables included lysis time which is time taken for turbidity to drop by 50% from maximum as a measure of lysis potential and maximum turbidity which is turbidity the scattering of light as a measure of fibrin clot density. Other biochemical analyses included N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T, cystatin C, C-reactive protein (CRP), and growth differentiation factor-15 (GDF-15), which were measured using sandwich immunoassays. Differential blood count was determined on EDTA-anticoagulated blood samples at randomization.

The scientists reported that after adjusting for CV risk factors, each 50% increase in lysis time was associated with CV death/spontaneous myocardial infarction (MI) and CV death alone. Similarly, each 50% increase in maximum turbidity was associated with increased risk of CV death. After adjustment for other prognostic biomarkers (leukocyte count, high-sensitivity C-reactive protein, high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide, and growth differentiation factor-15), the association with CV death remained significant for lysis time, but not for maximum turbidity.

The authors concluded that after adjustment for known clinical characteristics and risk factors, the study found that the patients with the longest clot lysis time had a 40% increased risk of recurrent myocardial infarction or death due to cardiovascular disease. Fibrin clots that are resistant to lysis independently predict adverse outcome in ACS patients. The study was published on January 29, 2018, in the European Heart Journal.

Related Links:
University of Sheffield


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.